Related Experiment Video
Updated: Jun 5, 2025
Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
Published on: December 18, 2016
The QIBA Profile for Dynamic Susceptibility Contrast MRI Quantitative Imaging Biomarkers for Assessing Gliomas.
Mark S Shiroishi1, Bradley J Erickson1, Leland S Hu1
1From the Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, Calif (M.S.S., S.C., Z.F., N.A., S.N.); Department of Radiology, Mayo Clinic, Rochester, Minn (B.J.E.); Department of Radiology, Mayo Clinic, Scottsdale, Ariz (L.S.H., Y.Z.); Division of Neuroradiology, Department of Radiology, Duke University School of Medicine, Durham, NC (D.P.B.); Invicro, Needham, Mass (L.B.); Clinical Imaging Group, Genentech, South San Francisco, Calif (L.C.B.); Imaging Core Laboratory, American College of Radiology, Philadelphia, Pa (M.A.B., L.C.); Section of Neuroradiology, Department of Diagnostic Imaging, Warren Alpert Medical School of Brown University, Providence, RI (J.L.B.); National Institute of Standards and Technology, Boulder, Colo (K.E.K.); Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, 149 13th St, CNY 2301, Charlestown, MA 02129 (J.E.K., L.R., O.W.); Barrows Neurologic Institute, Phoenix, Ariz (C.C.Q.); Cancer Systems Imaging, MD Anderson Cancer Center, Houston, Tex (C.C.Q.); Department of Radiology, Division of Abdominal Imaging, Hospital of the University of Pennsylvania, Philadelphia, Pa (M.A.R.); College of Undergraduate Studies, University of Central Florida, Orlando, Fla (L.R.); Department of Biophysics, Medical College of Wisconsin, Milwaukee, Wis (K.M.S.); Independent Consultant, Basel, Switzerland (G.Z.); and Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.O.).
Dynamic susceptibility contrast (DSC) MRI relative cerebral blood volume (rCBV) is crucial for glioma monitoring. A new RSNA profile establishes precision claims for longitudinal rCBV measurements, improving reproducibility for clinical use.
Area of Science:
- Neuroimaging
- Radiology
- Oncology
Background:
- Dynamic susceptibility contrast (DSC) MRI measures relative cerebral blood volume (rCBV), vital for tracking glioma progression and treatment response.
- Current rCBV quantification faces challenges in reproducibility across different settings, hindering clinical application.
- The RSNA DSC MRI Biomarker Committee aimed to standardize rCBV measurement precision.
Purpose of the Study:
- To establish statistics-based claims for the precision of longitudinal rCBV measurements in gliomas.
- To address the critical barrier of rCBV quantification reproducibility in clinical and research settings.
- To provide a framework for reliable longitudinal DSC MRI analysis in glioma patients.
Main Methods:
- Focused on the reproducibility of tissue-normalized area under the contrast agent concentration-time curve (AUC) values.
- Utilized within-subject coefficient of variation (wCV) data from previous reports for enhancing gliomas (wCV=0.31) and normal gray matter (wCV=0.40).
- Defined specific percentage change thresholds for longitudinal rCBV measurements with 95% confidence.
Main Results:
- For enhancing gliomas, an increase >182% or decrease >64% in tissue-normalized AUC indicates a significant change with 95% confidence.
- For normal gray matter, an increase >399% or decrease >80% in tissue-normalized AUC indicates a significant change with 95% confidence.
- These claims provide objective criteria for assessing longitudinal changes in rCBV.
Conclusions:
- The developed RSNA profile offers standardized precision claims for longitudinal rCBV measurements.
- This standardization is essential for the routine clinical and trial use of DSC MRI in glioma management.
- Future updates will incorporate technological advancements to further refine biomarker precision.
